Checkpoint Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CKPT and buy or sell other stocks, ETFs, and their options commission-free!About CKPT
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX.
CEOJames F. Oliviero, III, CFA
CEOJames F. Oliviero, III, CFA
Employees24
Employees24
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2014
Founded2014
Employees24
Employees24
CKPT Key Statistics
Market cap356.83M
Market cap356.83M
Price-Earnings ratio-3.78
Price-Earnings ratio-3.78
Dividend yield—
Dividend yield—
Average volume2.90M
Average volume2.90M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.50
52 Week high$4.50
52 Week low$1.80
52 Week low$1.80
Stock Snapshot
As of today, Checkpoint Therapeutics(CKPT) shares are valued at $4.26. The company's market cap stands at 356.83M, with a P/E ratio of -3.78.
Checkpoint Therapeutics(CKPT) stock opened on 2025-12-17 at —. The price climbed to — and dipped to —.
Checkpoint Therapeutics(CKPT) shares are trading with a volume of 0, against a daily average of 2.9M.
During the past year, Checkpoint Therapeutics(CKPT) stock moved between $1.80 at its lowest and $4.50 at its peak.
During the past year, Checkpoint Therapeutics(CKPT) stock moved between $1.80 at its lowest and $4.50 at its peak.
People also own
Based on the portfolios of people who own CKPT. This list is generated using Robinhood data, and it’s not a recommendation.